Amrallah A. Mohammed, Mohamed A Elbassuiony, Hanaa Rashied
{"title":"转移性三阴性乳腺癌:新时代的思考","authors":"Amrallah A. Mohammed, Mohamed A Elbassuiony, Hanaa Rashied","doi":"10.2478/fco-2018-0007","DOIUrl":null,"url":null,"abstract":"Abstract The heterogeneity of triple negative breast cancer (TNBC) is reflected in a bizarre response to therapy. Although it is chemotherapy sensitive, the failure is the usual pathway either in local or distance status. With progression in Gene Expression Profile (GEP) and other molecular techniques, TNBC is divided into sub-types with unique pathways. In the current review, we are trying to highlight based on the molecular classification of TNBC and the management based on every type.","PeriodicalId":38592,"journal":{"name":"Forum of Clinical Oncology","volume":"12 1","pages":"31 - 38"},"PeriodicalIF":0.0000,"publicationDate":"2021-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Metastatic Triple Negative Breast Cancer: The New Era of Thinking\",\"authors\":\"Amrallah A. Mohammed, Mohamed A Elbassuiony, Hanaa Rashied\",\"doi\":\"10.2478/fco-2018-0007\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Abstract The heterogeneity of triple negative breast cancer (TNBC) is reflected in a bizarre response to therapy. Although it is chemotherapy sensitive, the failure is the usual pathway either in local or distance status. With progression in Gene Expression Profile (GEP) and other molecular techniques, TNBC is divided into sub-types with unique pathways. In the current review, we are trying to highlight based on the molecular classification of TNBC and the management based on every type.\",\"PeriodicalId\":38592,\"journal\":{\"name\":\"Forum of Clinical Oncology\",\"volume\":\"12 1\",\"pages\":\"31 - 38\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Forum of Clinical Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2478/fco-2018-0007\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Forum of Clinical Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2478/fco-2018-0007","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
Metastatic Triple Negative Breast Cancer: The New Era of Thinking
Abstract The heterogeneity of triple negative breast cancer (TNBC) is reflected in a bizarre response to therapy. Although it is chemotherapy sensitive, the failure is the usual pathway either in local or distance status. With progression in Gene Expression Profile (GEP) and other molecular techniques, TNBC is divided into sub-types with unique pathways. In the current review, we are trying to highlight based on the molecular classification of TNBC and the management based on every type.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
